Sunday, November 15, 2026

How We Source Explore Search

Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source

Press releaseGlobeNewswire· March 28, 2026

Tribal Loans Are On The Rise — And TribalLoans.com Might Be the Reason Why

View original at globenewswire.com

Tribal Loans Are On The Rise — And TribalLoans.com Might Be the Reason Why New York, NY, March 27, 2026 (GLOBE NEWSWIRE) -- Let's be honest…

Opening lines of the source · GlobeNewswire · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Platform runs only soft credit inquiry that won't leave a mark on credit file
60% confidence
Application process takes around two minutes
60% confidence
Approved applicants can receive funds via ACH transfer on the day they apply
60% confidence
Platform has a 4.9 out of 5 customer rating
60% confidence
TribalLoans.com has served over 2,000,000 borrowers across the US
60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic

Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

Ford Motor Company

Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,995

facts traced to their source, and we flag the ones that don't hold up.

101 entities tracked4,995 facts checked against source5,580 source documents archived

Query this data → isubstrate.com